首页> 美国卫生研究院文献>British Journal of Pharmacology and Chemotherapy >Mechanisms underlying the modulatory action of platelet activating factor (PAF) on the upregulation of kinin B1 receptors in the rat paw
【2h】

Mechanisms underlying the modulatory action of platelet activating factor (PAF) on the upregulation of kinin B1 receptors in the rat paw

机译:血小板活化因子(PAF)对大鼠爪激肽B1受体上调的调节作用的潜在机制

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

class="enumerated" style="list-style-type:decimal">The present study evaluated the ability of the administration of platelet activating factor (PAF) to induce the upregulation of B1 receptors in the rat paw.Local treatment with PAF resulted in a time-dependent increase of oedema formation induced by the B1 receptor agonist des-Arg9-BK (des-Arg9-bradykinin), but not by the B2 receptor agonist tyrosine8-bradykinin. Functional upregulation of B1 receptors was accompanied by a prominent increase of B1 receptor mRNA expression in the rat paw.In PAF-treated paws, des-Arg9-BK-induced oedema formation was significantly inhibited by the B1 receptor antagonists des-Arg9-[Leu8]-BK and R-715. The effects of PAF pretreatment were receptor operated, as assessed by the effects of the PAF receptor antagonist WEB2086 or by desensitisation of PAF receptors.The protein synthesis inhibitor cycloheximide, the anti-inflammatory steroid dexamethasone or the nuclear factor (NF-κB) blockers pyrrolidine-dithiocarbamate (PDTC) and Nα-tosyl-L-chloromethylketone significantly blocked the functional upregulation of B1 receptors.The selectin inhibitor fucoidin, an anti-CD18 antibody or an anti-rat neutrophil antiserum, also significantly prevented des-Arg9-BK-induced paw oedema in rats pretreated with PAF.Intradermal injection of PAF induced a 25-fold increase of myeloperoxidase activity in the rat paw, a response that was significantly inhibited by fucoidin, anti-CD-18, anti-rat neutrophil antiserum or PDTC.Local treatment with PAF also resulted in a marked increase of NF-κB activation, an effect largely prevented by PDTC or by the anti-rat neutrophil antiserum.Collectively, the present results indicate that the induction of B1 receptors following treatment with the chemotatic mediator PAF is dependent on the recruitment of neutrophils, an event that is under the control of adhesion molecules, protein synthesis and NF-κB activation. These findings provide new insights into the role played by cell migration and chemotatic factors on B1 receptor upregulation in vivo.
机译:class =“ enumerated” style =“ list-style-type:decimal”> <!-list-behavior =枚举前缀-word = mark-type = decimal max-label-size = 0-> 本研究评估了给予血小板活化因子(PAF)诱导大鼠爪中B1受体上调的能力。 PAF局部治疗可导致时间依赖性的水肿形成增加是由B1受体激动剂des-Arg 9 -BK(des-Arg 9 -缓激肽)引起的,而不是由B2受体激动剂酪氨酸 8 引起的-缓激肽。 B1受体的功能上调伴随着大鼠爪中B1受体mRNA表达的显着增加。 在PAF处理的爪中,des-Arg 9 -BK引起的水肿B1受体拮抗剂des-Arg 9 -[Leu 8 ]-BK和R-715显着抑制其形成。通过PAF受体拮抗剂WEB2086的作用或PAF受体的脱敏作用,可以评估PAF预处理的作用。 蛋白质合成抑制剂环己酰亚胺,抗炎类固醇地塞米松或核因子(NF-κB)阻滞剂吡咯烷-二硫代氨基甲酸酯(PDTC)和Nα-甲苯磺酰基-L-氯甲基酮显着阻断B1受体的功能上调。 选择素抑制剂岩藻依汀,抗CD18抗体或抗大鼠中性粒细胞抗血清,也能显着预防des-Arg 9 -BK诱导的PAF所致大鼠爪水肿。 皮内注射PAF可使髓过氧化物酶活性增加25倍在大鼠爪中,岩藻糖蛋白,抗CD-18,抗大鼠中性粒细胞抗血清或PDTC显着抑制了这种反应。 用PAF局部治疗还导致NF-κB活化显着增加,PDTC或抗鼠药在很大程度上避免了这种作用 总的来说,目前的结果表明,用化学介质PAF治疗后,B1受体的诱导取决于中性粒细胞的募集,这一事件在粘附分子,蛋白质合成的控制下和NF-κB激活。这些发现为细胞迁移和趋化因子在体内B1受体上调中的作用提供了新的见解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号